SAB Biotherapeutics (SABS) - צמיחת רווחים בשנה הנוכחית

SAB Biotherapeutics is implementing software robots and automated screening to accelerate drug development. The annual percentage growth in net income per share illustrates the yield dynamics, where -39.40 represents the current level of the metric. Success is based on a proprietary polyclonal antibody platform, which guarantees monopoly income, and a team of leading immunologists working under exceptional conditions.

This indicator determines the year-over-year dynamics of net income per share. By analyzing the comparable growth rate of earnings per share over the year, an investor assesses the efficiency of capital generation. The metric is calculated as the percentage deviation of the current EPS from the value of the same period last year. A positive trend confirms business scaling. For SAB Biotherapeutics (SABS), this reflects the commercial return from licensing the DiversitAb platform in alliances with pharma behemoths.